# OnCo record olympiad (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/olympiad/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "olympiad", "NCT02000622" ;
  schema:name "OlympiAD"@en ;
  schema:description "OlympiAD was the first trial to show a PARP inhibitor tablet beats chemotherapy in breast cancer, delaying progression by about three months in women with an inherited BRCA mutation and with fewer side effects, though it did not lengthen life overall."@en ;
  schema:url <https://onco.cc/trials/olympiad/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02000622>, <https://doi.org/10.1056/NEJMoa1706450> ;
  onco:status "positive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/tnbc-metastatic/>, <https://onco.cc/cancers/hr-positive-metastatic-post-cdk46/> ;
  onco:technologies <https://onco.cc/technologies/parp-inhibitor/> ;
  onco:targets <https://onco.cc/targets/brca/>, <https://onco.cc/targets/parp/> ;
  onco:drugs <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/eribulin/>, <https://onco.cc/drugs/vinorelbine/> ;
  onco:terms <https://onco.cc/terms/gbrca-mutation/> .